Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective.
Savvas S IoannouYiola MarcouEleni KakouriMichael A TaliasPublished in: International journal of environmental research and public health (2020)
The study revealed that adjuvant trastuzumab for one year in female HER2-positive early breast cancer can be considered cost-effective.